How Trump's New Drug Tariffs Affect Pharmaceutical Manufacturing Operations

On April 2, 2026, The Trump administration announced a new tariff framework targeting pharmaceutical imports, one that will reshape sourcing, manufacturing, and pricing decisions across the industry.1 The policy applies to patented medications and their APIs, with a base rate of 100%, though the structure includes several pathways that will determine whether and how the levies actually affect operations.

Companies that have already drafted drug pricing agreements with the Health and Human Services Department, or are currently in active negotiations while simultaneously building domestic manufacturing capacity, are exempt from the tariffs entirely.1 Thirteen companies have already signed pricing agreements under the administration's most favored nation (MFN) policy, with four additional firms currently under negotiations. This initiative ties US drug prices to lower international benchmark and carry a 3-year tariff exemption.

For companies who have yet to make deals, the administration is offering a transitional rate of 20% for companies that commit to onshoring production, a figure that climbs to 100% in 4 years’ time.1 Larger companies have 120 days before the full rate takes effect. Smaller companies that rely on contract manufacturers have 180 days.

Country of origin also factors into the tariff structure. The European Union, Japan, South Korea, and Switzerland face a 15% rate.1 The United Kingdom faces a 10% rate, in part because its government has agreed to raise what it pays for pharmaceuticals. These nations have received these reductions through greater manufacturing deals with America.

Why Are These Increases Happening Now?

The key is the supply chain.1 The sector-specific tariffs follow a Commerce Department investigation that determined certain pharmaceutical imports pose a national security risk to the United States.

Anthony Lakavage, executive vice president and head of Global External Affairs, US Pharmacopeia (USP), stated in an interview with PharmTech,“We're seeing a concern where the medicine supply chain could be used with trade tools as, almost weaponized," he said, "and that creates a vulnerability that I think we're not comfortable with from the perspective of both national security and, of course, patient care."

Peter Brereton, Chief Executive Officer, Tecsys, told PharmTech, ”Yesterday’s announcement of new U.S. tariffs on certain patented medicines and ingredients is another reminder that healthcare and life sciences supply chains are operating in an extremely high‑volatility environment. As policies shift, the organizations that fare best are those with a strong supply chain posture: end‑to‑end inventory accuracy, traceability and governance, supplier and sourcing resilience, and the ability to detect exceptions early and act quickly. For providers and distributors, the priority is continuity — protecting patient care while managing cost and compliance. That requires tighter control over inventory and replenishment, clearer insight into supplier performance and lead times, and the operational discipline to adapt without disruption. The most durable risk mitigation isn’t a single tactic, it’s building the capabilities to respond fast, measure impact and keep product moving.”

Valerie Bandy, Vice President, Pharmacy, Tecsys, told PharmTech, “Tariff changes on patented medicines increase uncertainty across the drug supply chain and that uncertainty shows up at the point of care: delayed access, substitution challenges and added pressure on already‑strained pharmacy and supply teams. The best defense is a strong supply chain posture that prioritizes patient continuity: accurate item and lot control, real‑time visibility to where critical products are, strong vendor relationships and the workflows to respond quickly when supply or cost conditions change. In practical terms, that means minimizing waste and expiries, strengthening replenishment discipline, and maintaining traceability and documentation that stand up to compliance expectations even as market dynamics shift. When volatility increases, resilient supply chains don’t just see problems sooner, they are built to correct them faster.”

Foreign nations like China and India control the majority of manufacturing of API’s globally. The administration’s policy changes and tariffs initiatives are designed to build a robust domestic supply chain within the US network that will hold strong if those nations attempt decrease their exports. The administration has noted that there are already $400 billion in commitments to reshore manufacturing during the current presidential term.1

Certain niches are not covered under this framework as genetic products, biosimilars, and related ingredients are not subject to tariffs at this time, though the administration will reassess that in 1 year.1 Certain specialty pharmaceutical products, including those for animal health and treatments for rare conditions, will be exempt if those medicines come from countries with the aforementioned trade deals.

What Other Stipulations Come with the New Tariffs?

The proclamation does not rely solely on voluntary compliance.2 It establishes external audits alongside the tariff structure, and companies that fall out of compliance face tariff increases applied to both future and past imports. The administration has also signaled this is not an isolated pharmaceutical policy. Parallel Section 232 investigations are already underway in adjacent sectors including personal protective equipment, medical consumables, medical devices, and robotics. This initiative suggests the supply chain security framework being applied to pharmaceuticals may soon extend to other inputs that manufacturing and development operations depend on.

References

1. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs. CNBC. April 2, 2026. Accessed April 3, 2026. https://www.cnbc.com/2026/04/02/trump-pharmaceutical-tariffs-100percent.html
2. The White House. Fact sheet: President Donald J. Trump bolsters national security and strengthens U.S. supply chains by imposing tariffs on patented pharmaceutical products. Published April 1, 2026. Accessed April 3, 2026. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products/